Tetrahydrocannabivarin (THCV): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Tetrahydrocannabivarin (THCV) is a chemical in the Cannabis sativa plant. It doesn't seem to affect thinking like some other chemicals found in this plant.

Tetrahydrocannabivarin seems to affect certain nerve cells in the brain. These effects might help to reduce seizures, regulate emotional reactions to food, and reduce cravings for addictive substances.

There is interest in using tetrahydrocannabivarin for diabetes, pain, seizures, and other conditions, but there is no good scientific evidence to support these uses.

Uses & Effectiveness

We currently have no information for Tetrahydrocannabivarin (THCV) overview.

Side Effects

When taken by mouth: Tetrahydrocannabivarin is possibly safe for adults when used for up to 13 weeks. It isn't clear what side effects it might cause.

Special Precautions and Warnings

When taken by mouth: Tetrahydrocannabivarin is possibly safe for adults when used for up to 13 weeks. It isn't clear what side effects it might cause.

Pregnancy and breast-feeding:There isn't enough reliable information to know if tetrahydrocannabivarin is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Interactions

We currently have no information for Tetrahydrocannabivarin (THCV) overview.

Dosing

There isn't enough reliable information to know what an appropriate dose of tetrahydrocannabivarin might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.

View References

REFERENCES:

97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016 Oct;39(10):1777-86.

Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ??-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219(3):859-73.

Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and ?(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170(3):671-8.

Bolognini D, Costa B, Maione S, et al. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol. 2010;160(3):677-87.

Cascio MG, Zamberletti E, Marini P, Parolaro D, Pertwee RG. The phytocannabinoid, ??-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects. Br J Pharmacol. 2015;172(5):1305-18.

Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol. 2016;30(2):140-51.

Hill AJ, Weston SE, Jones NA, et al. ??-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia. 2010;51(8):1522-32.

Pagano E, Montanaro V, Di Girolamo A, et al. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol. Nat Prod Commun. 2015;10(6):1009-12.

Romano B, Pagano E, Orlando P, et al. Pure ?9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in ?9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacol Res. 2016;113(Pt A):199-208.

Rzepa E, Tudge L, McCabe C. The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. Int J Neuropsychopharmacol. 2015;19(2). pii: pyv092.

Tudge L, Williams C, Cowen PJ, McCabe C. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol. 2014;18(6). pii: pyu094.

Wargent ET, Zaibi MS, Silvestri C, et al. The cannabinoid ?(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. 2013;3:e68.

Xi ZX, Muldoon P, Wang XF, et al. ?8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. Br J Pharmacol. 2019.

Espadas I, Keifman E, Palomo-Garo C, et al. Beneficial effects of the phytocannabinoid delta(9)-THCV in L-DOPA-induced dyskinesia in Parkinson's disease. Neurobiol Dis. 2020;141:104892.

Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10(1):20405.

Straiker A, Wilson S, Corey W, et al. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. Molecules 2021;26(17):5352.

Raïch I, Rivas-Santisteban R, Lillo A, et al. Similarities and differences upon binding of naturally occurring ?(9)-tetrahydrocannabinol-derivatives to cannabinoid CB(1) and CB(2) receptors. Pharmacol Res 2021;174:105970.

Moore CF, Weerts EM, Kulpa J, et al. Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain. Cannabis Cannabinoid Res 2023;8(S1):S51-S61.

Gojani EG, Wang B, Li DP, Kovalchuk O, Kovalchuk I. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. Molecules 2023;28(18):6487.

Peters EN, MacNair L, Harrison A, et al. A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral ?(8)-Tetrahydrocannabivarin in Healthy Participants. Cannabis Cannabinoid Res 2023;8(S1):S71-S82.

Schwarz AM, Kobeci D, Mancuso JA, et al. Select Minor Cannabinoids from Cannabis sativa Are Cannabimimetic and Antinociceptive in a Mouse Model of Chronic Neuropathic Pain. J Pharmacol Exp Ther 2024;391(2):214-221.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.